Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety

Chronic spontaneous urticaria (CSU) is characterized by the recurrence of itchy hives and/or angioedema for greater than six weeks, with no known external trigger. Omalizumab, a humanized, recombinant, monoclonal anti-IgE antibody, is the only approved add-on therapy for H1-antihistamine refractory...

Descripción completa

Detalles Bibliográficos
Autor: Giménez Arnau, Anna Maria
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2017
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/33611
Acceso en línea:http://hdl.handle.net/10230/33611
http://dx.doi.org/10.1080/14712598.2017.1285903
Access Level:acceso abierto
Palabra clave:Urticària -- Tractament
Anti-IgE
Chronic idiopathic urticaria
Chronic spontaneous urticaria
Chronic urticaria
Omalizumab
id ES_c3ef1484eee51e177fd2da889bc3b8a8
oai_identifier_str oai:recercat.cat:10230/33611
network_acronym_str ES
network_name_str España
repository_id_str
spelling Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safetyGiménez Arnau, Anna MariaUrticària -- TractamentAnti-IgEChronic idiopathic urticariaChronic spontaneous urticariaChronic urticariaOmalizumabChronic spontaneous urticaria (CSU) is characterized by the recurrence of itchy hives and/or angioedema for greater than six weeks, with no known external trigger. Omalizumab, a humanized, recombinant, monoclonal anti-IgE antibody, is the only approved add-on therapy for H1-antihistamine refractory CSU patients. Areas covered: The objective of this article is to discuss the mechanism of action, pharmacokinetics and pharmacodynamics of omalizumab for the treatment of CSU. The review also summarizes efficacy and safety data from proof-of-concept, phase II (X-CUISITE, MYSTIQUE), and pivotal phase III omalizumab studies (ASTERIA I, ASTERIA II, and GLACIAL). Expert opinion: Omalizumab is a clinically effective and safe biological therapy for treating H1-antihistamine refractory CSU patients. It significantly reduces CSU symptoms (hives, itch and angioedema), and improves patient health-related quality of life. While omalizumab is already integral to the treatment of antihistamine refractory CSU, widespread use will depend on legal and economic factors, as well as improvements in the early and accurate diagnosis of CSU patients who would benefit from treatment.Taylor & Francis (Routledge)20182017info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/33611http://dx.doi.org/10.1080/14712598.2017.1285903reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésExpert Opinion on Biological Therapy. 2017 Mar;17(3):375-85© Taylor & Francis. This is an electronic version of an article published in Giménez-Arnau AM. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety. Expert Opin Biol Ther. 2017 Mar;17(3):375-385. Expert opinion on biological therapy is available online at: www.tandfonline.com http://www.tandfonline.com/doi/abs/10.1080/14712598.2017.1285903info:eu-repo/semantics/openAccessoai:recercat.cat:10230/336112026-05-29T05:05:01Z
dc.title.none.fl_str_mv Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety
title Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety
spellingShingle Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety
Giménez Arnau, Anna Maria
Urticària -- Tractament
Anti-IgE
Chronic idiopathic urticaria
Chronic spontaneous urticaria
Chronic urticaria
Omalizumab
title_short Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety
title_full Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety
title_fullStr Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety
title_full_unstemmed Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety
title_sort Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety
dc.creator.none.fl_str_mv Giménez Arnau, Anna Maria
author Giménez Arnau, Anna Maria
author_facet Giménez Arnau, Anna Maria
author_role author
dc.subject.none.fl_str_mv Urticària -- Tractament
Anti-IgE
Chronic idiopathic urticaria
Chronic spontaneous urticaria
Chronic urticaria
Omalizumab
topic Urticària -- Tractament
Anti-IgE
Chronic idiopathic urticaria
Chronic spontaneous urticaria
Chronic urticaria
Omalizumab
description Chronic spontaneous urticaria (CSU) is characterized by the recurrence of itchy hives and/or angioedema for greater than six weeks, with no known external trigger. Omalizumab, a humanized, recombinant, monoclonal anti-IgE antibody, is the only approved add-on therapy for H1-antihistamine refractory CSU patients. Areas covered: The objective of this article is to discuss the mechanism of action, pharmacokinetics and pharmacodynamics of omalizumab for the treatment of CSU. The review also summarizes efficacy and safety data from proof-of-concept, phase II (X-CUISITE, MYSTIQUE), and pivotal phase III omalizumab studies (ASTERIA I, ASTERIA II, and GLACIAL). Expert opinion: Omalizumab is a clinically effective and safe biological therapy for treating H1-antihistamine refractory CSU patients. It significantly reduces CSU symptoms (hives, itch and angioedema), and improves patient health-related quality of life. While omalizumab is already integral to the treatment of antihistamine refractory CSU, widespread use will depend on legal and economic factors, as well as improvements in the early and accurate diagnosis of CSU patients who would benefit from treatment.
publishDate 2017
dc.date.none.fl_str_mv 2017
2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/33611
http://dx.doi.org/10.1080/14712598.2017.1285903
url http://hdl.handle.net/10230/33611
http://dx.doi.org/10.1080/14712598.2017.1285903
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Expert Opinion on Biological Therapy. 2017 Mar;17(3):375-85
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis (Routledge)
publisher.none.fl_str_mv Taylor & Francis (Routledge)
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418838456532992
score 15,81155

Similares en LA Referencia